Brookfield Infrastructure Partners LP vs Cassava Sciences Inc — how do they compare? Brookfield Infrastructure Partners LP trades at $38.19 (market cap $17.38B), while Cassava Sciences Inc trades at $1.11 (market cap $52.66M). The key difference: Brookfield Infrastructure Partners LP is far larger — about 330× Cassava Sciences Inc's market cap, and Brookfield Infrastructure Partners LP pays a 4.77% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| BIP | FLNA | |
|---|---|---|
Market Cap | $17.38B | $52.66M |
Sector | Industrials | Health |
52-Week High | $40.08 | $4.64 |
52-Week Low | $29.81 | $1.09 |
Enterprise Value | $79.06B | -$33.92M |
Dividend Yield | 4.77% | — |
Signals from Pluang's Aura AI — not financial advice
Brookfield Infrastructure Partners (BIP) trades at $37.61, down slightly by 0.11% today. The stock shows bullish technical signals with strong analyst support (81% buy ratings) and a $45.50 consensus price target. Recent earnings have been mixed with one beat and two misses, but the company maintains robust cash flows with $5.97B from operations in 2025. BIP offers a 5% dividend yield with recent H1-26 payment of $0.46 per share.
BIP presents a compelling value opportunity with discounted valuation metrics (P/S 0.73, EV/EBITDA 7.55) and strong infrastructure assets. However, investors face risks from recent earnings volatility, high P/E ratio of 57.8, and declining profit margins. The company's global infrastructure portfolio provides inflation protection and stable cash flows, supporting the bullish analyst consensus despite near-term headwinds.
FLNA trades at $1.15, down 2.54% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company continues to report losses, with a net income of -$90.97M in 2025 and negative cash flow, though it has beaten EPS estimates for the last three quarters. Recent news highlights ongoing development in its TSC-related epilepsy therapies.
Despite consistent earnings beats, FLNA's negative profitability and cash burn pose significant risks. Analyst sentiment is positive with a 66.7% buy rating, but the stock's outlook depends heavily on clinical success and future funding. Investors should weigh the high-risk, high-reward nature of this biotech play.
Trailing returns across standard periods
Latest headlines on both assets
Brookfield Infrastructure owns and operates high-quality global assets across utilities, transport, midstream, and data sectors. It focuses on generating stable, long-term cash flows from essential infrastructure.
Read more on BIP →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →